Bortezomib was approved for medical use in the United States in 2003 and in Europe in 2004. Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.. Reference standards of Bortezomib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
stdClass Object ( [pname] => (R)-Hydroperoxy Des(boric Acid) Bortezomib [catalogue_number] => PA 02 79660 [category_ids] => 80,79,75 [chemical_name] => [weight] => 372.42 [form] => C19H24N4O4 [cas] => 886979-78-8 [pslug] => 886979-78-8-r-hydroperoxy-des-boric-acid-bortezomib-pa0279660 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 02 79660
CAS :
Molecular Formula : C19H24N4O4
Molecular Weight : 372.42
stdClass Object ( [pname] => (S)-Hydroperoxy Des(boric Acid) Bortezomib [catalogue_number] => PA 02 79670 [category_ids] => 75,79,80 [chemical_name] => [weight] => 372.43 [form] => C19H24N4O4 [cas] => 886979-81-3 [pslug] => 886979-81-3-s-hydroperoxy-des-boric-acid-bortezomib-pa0279670 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 02 79670
Molecular Weight : 372.43
stdClass Object ( [pname] => Bortezomib L-Phenylalanyl Analog [catalogue_number] => PA 02 79720 [category_ids] => 76,71,90,69,70,78,82,79,75 [chemical_name] => [weight] => 531.42 [form] => C28H34BN5O5 [cas] => 1194235-41-0 [pslug] => 1194235-41-0-bortezomib-l-phenylalanyl-analog-pa0279720 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 02 79720
Molecular Formula : C28H34BN5O5
Molecular Weight : 531.42
stdClass Object ( [pname] => (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetic Acid Salt [catalogue_number] => PA 02 79750 [category_ids] => ,79,90,69,70, [chemical_name] => [weight] => 379.23 [form] => C17H29BF3NO4 [cas] => 179324-87-9 [pslug] => 179324-87-9-alpha-r-1s-2s-3r-5s-pinanediol-1-amino-3-methylbutane-1-boronate-trifluoroacetic-acid-salt-pa0279750 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 02 79750
Molecular Formula : C17H29BF3NO4
Molecular Weight : 379.23
stdClass Object ( [pname] => (αS)-α-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-benzenepropanamide Monohydrochloride [catalogue_number] => PA 02 79840 [category_ids] => ,79,90,69,70,82, [chemical_name] => [weight] => 434.81 [form] => C23H36BClN2O3 [cas] => 205393-21-1 [pslug] => 205393-21-1-alpha-s-alpha-amino-n-1r-1-3as-4s-6s-7ar-hexahydro-3a-5-5-trimethyl-4-6-methano-1-3-2-benzodioxaborol-2-yl-3-methylbutyl-benzenepropanamide-monohydrochloride-pa0279840 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 02 79840
Molecular Formula : C23H36BClN2O3
Molecular Weight : 434.81
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
